Abstract：Objective: To investigate the expression and clinical significance of serum LncRNA CASC15 and LncRNA MALAT1 in hemodialysis patients with end-stage renal disease. Methods: Patients with end-stage renal disease who underwent regular dialysis treatment in our hospital from January 2019 to December 2020 were selected as the research group,and 62 patients with CKD stage Ⅲ-Ⅳ who started dialysis treatment for the first time in our hospital were randomly selected according to the ratio of 1:1 as the control group.Blood samples were tested for creatinine (SCr),uric acid (UA),eGFR,total cholesterol (TC),triglycerides (TG),urea (BUN),haemoglobin,C-reactive protein (CRP),calcium and phosphorus by real-time fluorescence quantitative polymerase chain reaction (RT-PCR) based on SYBR Green method to amplify the target sequences.Patients in the study group were followed up for the occurrence of clinical endpoint times within 1 year of starting dialysis. Results: The expressions of serum LncRNA CASC15 and LncRNA MALAT1 in the study group were significantly higher than those in the control group (P>0.05).); LncRNA MALAT1 high expression of SCr,UA,BUN was higher than LncRNA MALAT1 low expression group,eGFR and hemoglobin were lower than low expression group,the difference was statistically significant (P<0.05); uremic patients with different LncRNA CASC15 expression levels developed cardiovascular disease.There were statistically significant differences in events and all-cause mortality (P<0.05),and differences in the expression levels of different LncRNA CASC15 and LncRNA MALAT1 for giving up treatment (all-cause death) were statistically significant (P<0.05).There was no significant difference in the incidence of cerebrovascular accident,serious infection and gastrointestinal bleeding among the expression level groups (P>0.05). Conclusion: LncRNA CASC15 and LncRNA MALAT1 are significantly up-regulated in the serum of end-stage renal disease hemodialysis patients,which are closely related to the clinical parameters of patients and the time of dialysis clinical endpoints,and are expected to be therapeutic targets for in-depth research.
2022, Vol. 28 
冀公网安备13080202000677号